Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

Raushan T. Kurmasheva, C. Patrick Reynolds, Min H. Kang, Cecilia Allievi, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

4 Scopus citations


Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC50 value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.

Original languageEnglish (US)
Pages (from-to)922-924
Number of pages3
JournalPediatric Blood and Cancer
Issue number5
StatePublished - May 2014
Externally publishedYes



  • Developmental therapeutics
  • Preclinical testing
  • Topoisomerase 2 inhibitor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this